This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/pdb/
n7http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/kegg-drug/
n6http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n8http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00256/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00256
rdf:type
n3:Drug
n3:description
A tetracycline with a 7-chloro substitution. [PubChem]
n3:generalReferences
# "Link":http://www.medsafe.govt.nz/profs/Datasheet/t/Tetralysalcap.htm # Meynadier J, Alirezai M: Systemic antibiotics for acne. Dermatology. 1998;196(1):135-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9557248
n3:group
approved
n3:indication
For the treatment of infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Lymecycline is also used commonly as a prophylactic treatment for infection by <i>Bacillus anthracis</i> (anthrax). It is also effective against <i>Yersinia pestis</i> and malaria and is also prescribed for the treatment of Lyme disease.
n3:manufacturer
n7:271B40AD-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00256 n14:DB00256
dcterms:title
Lymecycline
adms:identifier
n11:24757945 n12:46505518 n13:59040 n15:D06884 n16:CTC n17:23501197 n18:DB00256 n19:PA164747190 n21:Lymecycline
n3:mechanismOfAction
Lymecycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Lymecycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. Cells become resistant to lymecycline by at least two mechanisms: efflux and ribosomal protection. In efflux, a resistance gene encodes a membrane protein that actively pumps lymecycline out of the cell. This is the mechanism of action of the tetracycline resistance gene on the artificial plasmid pBR322. In ribosomal protection, a resistance gene encodes a protein which binds to the ribosome and prevents lymecycline from acting on the ribosome.
n3:packager
n7:271B40AC-363D-11E5-9242-09173F13E4C5 n7:271B40AB-363D-11E5-9242-09173F13E4C5
n3:synonym
N(2)-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline Limeciclina Tetracycline-L-methylene lysine Lymecyclinum Tetracycline-L-methylenelysine (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide N-Lysinomethyltetracycline N6-((4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)methyl)lysine
n3:toxicity
Adverse effects include nausea, vomiting, diarrhoea, glossitis, enterocolitis, dysphagia, dermatitis, hypersensitivity reactions, proctitis, and vaginitis.
n3:foodInteraction
Do not to take any indigestion remedies, iron or zinc supplements at the same time as this medicine.
n3:synthesisReference
Willis L. Winstrom, "Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions." U.S. Patent US06844006, issued January 18, 2005.
n8:hasConcept
n9:M0012776
n3:IUPAC-Name
n4:271B40B2-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B40B8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B40B7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B40B4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B40B5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B40B6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B40B0-363D-11E5-9242-09173F13E4C5 n4:271B40C8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B40C9-363D-11E5-9242-09173F13E4C5 n4:271B40B1-363D-11E5-9242-09173F13E4C5 n4:271B40AE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B40AF-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:J01AA04
n3:H-Bond-Acceptor-Count
n4:271B40BE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B40BF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B40B9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B40BA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B40BC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B40BB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B40BD-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption is fast and efficient. Bioavailability is 100% following oral administration.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
992-21-2
n3:category
n3:Bioavailability
n4:271B40C4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B40C6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B40C7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B40C3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B40C2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B40C5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B40B3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B40C0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B40C1-363D-11E5-9242-09173F13E4C5